197 related articles for article (PubMed ID: 19755984)
21. The nuclear receptor coactivator PGC-1alpha exhibits modes of interaction with the estrogen receptor distinct from those of SRC-1.
Bourdoncle A; Labesse G; Margueron R; Castet A; Cavaillès V; Royer CA
J Mol Biol; 2005 Apr; 347(5):921-34. PubMed ID: 15784253
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha activation of CYP7A1 during food restriction and diabetes is still inhibited by small heterodimer partner.
Shin DJ; Osborne TF
J Biol Chem; 2008 May; 283(22):15089-96. PubMed ID: 18385139
[TBL] [Abstract][Full Text] [Related]
23. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
24. Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial.
Zhu L; Chow LW; Loo WT; Guan XY; Toi M
Clin Cancer Res; 2004 Jul; 10(14):4639-44. PubMed ID: 15269135
[TBL] [Abstract][Full Text] [Related]
25. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
Haugan Moi LL; Hauglid Flågeng M; Gandini S; Guerrieri-Gonzaga A; Bonanni B; Lazzeroni M; Gjerde J; Lien EA; DeCensi A; Mellgren G
Clin Cancer Res; 2010 Apr; 16(7):2176-86. PubMed ID: 20332317
[TBL] [Abstract][Full Text] [Related]
26. Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (ERRalpha): crystal structure of ERRalpha ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1alpha.
Kallen J; Schlaeppi JM; Bitsch F; Filipuzzi I; Schilb A; Riou V; Graham A; Strauss A; Geiser M; Fournier B
J Biol Chem; 2004 Nov; 279(47):49330-7. PubMed ID: 15337744
[TBL] [Abstract][Full Text] [Related]
27. Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
Hardy DB; Janowski BA; Chen CC; Mendelson CR
Mol Endocrinol; 2008 Aug; 22(8):1812-24. PubMed ID: 18483177
[TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptor gamma, coactivator 1α enhances local estrogen biosynthesis by stimulating aromatase activity in endometriosis.
Suganuma I; Mori T; Ito F; Tanaka Y; Sasaki A; Matsuo S; Kusuki I; Kitawaki J
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1191-8. PubMed ID: 24654751
[TBL] [Abstract][Full Text] [Related]
29. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
30. Evolution of endocrine adjuvant therapy for early breast cancer.
Lønning PE
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S19-30. PubMed ID: 20374026
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
32. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
Shibahara Y; Miki Y; Onodera Y; Hata S; Chan MS; Yiu CC; Loo TY; Nakamura Y; Akahira J; Ishida T; Abe K; Hirakawa H; Chow LW; Suzuki T; Ouchi N; Sasano H
J Pathol; 2012 Jul; 227(3):357-66. PubMed ID: 22407818
[TBL] [Abstract][Full Text] [Related]
33. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
34. Peroxisome proliferator-activated receptor-γ coactivator 1α-mediated pathway as a possible therapeutic target in endometriosis.
Kataoka H; Mori T; Okimura H; Matsushima H; Ito F; Koshiba A; Tanaka Y; Akiyama K; Maeda E; Sugahara T; Tarumi Y; Kusuki I; Khan KN; Kitawaki J
Hum Reprod; 2019 Jun; 34(6):1019-1029. PubMed ID: 31119261
[TBL] [Abstract][Full Text] [Related]
35. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
36. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
37. Distinct nuclear receptor expression in stroma adjacent to breast tumors.
Knower KC; Chand AL; Eriksson N; Takagi K; Miki Y; Sasano H; Visvader JE; Lindeman GJ; Funder JW; Fuller PJ; Simpson ER; Tilley WD; Leedman PJ; Graham J; Muscat GE; Clarke CL; Clyne CD
Breast Cancer Res Treat; 2013 Nov; 142(1):211-23. PubMed ID: 24122391
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha requires coactivators peroxisomal proliferator activated receptor-gamma coactivator 1alpha and steroid receptor coactivator 1.
Martínez-Jiménez CP; Castell JV; Gómez-Lechón MJ; Jover R
Mol Pharmacol; 2006 Nov; 70(5):1681-92. PubMed ID: 16882880
[TBL] [Abstract][Full Text] [Related]
39. Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells.
Bai Y; Giguére V
Mol Endocrinol; 2003 Apr; 17(4):589-99. PubMed ID: 12554772
[TBL] [Abstract][Full Text] [Related]
40. Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Selli C; Turnbull AK; Pearce DA; Li A; Fernando A; Wills J; Renshaw L; Thomas JS; Dixon JM; Sims AH
Breast Cancer Res; 2019 Jan; 21(1):2. PubMed ID: 30616553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]